business news in context, analysis with attitude

CNBC repots that the US Food and Drug Administration (FDA) has scheduled its first public hearing on the legalization of CBD - the non-psychoactive compound found in the cannabis - for May 31.

According to the story, “The agency wants data on CBD’s safety in food products and feedback on how it might regulate manufacturing, marketing and labeling, according to a notice posted Tuesday in the Federal Register … Congress legalized CBD derived from hemp in December.
This was supposed to lead to a surge in consumer products infused with the cannabis compound. However, the FDA’s rules prohibiting the addition of CBD to food and drinks have kept most large companies on the sidelines, though a number of start-ups have jumped in anyway.”


MarketWatch reports that Unilever-owned Schmidt’s Naturals plans to launch “a line of hemp-oil deodorants that will be available at certain retailers,” to be followed by “a separate range of CBD products” - if the company is confident that such a product line complies with all legal requirements.

CBD, a non-intoxicating ingredient in the cannabis plant, “was expected to be fully legalized along with hemp as part of the December Farm Bill, but instead it was moved under the purview of the U.S. Food and Drug Administration from the Drug Enforcement Administration,” the story says. “That’s because the FDA views it as a drug.

“CBD is an ingredient in the only cannabis-based drug that has won FDA approval as a treatment for severe forms of childhood epilepsy. The FDA has promised to hold talks on regulating the substance this month and outgoing commissioner Scott Gottlieb said he would seek pathways for approval. But until those have been created, the FDA is not allowing companies to add CBD to food, beverages or cosmetics, forcing many companies to put their plans on hold.”
KC's View: